Company Poltreg S.A.

Equities

PTG

PLPLTRG00038

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly revenue - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Warsaw S.E. Other stock markets 11:55:46 2024-05-15 EDT			5-day change	1st Jan Change
49.4 ^PLN	+0.82%		+2.92%	-0.80%

04-18	Poltreg S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-11	Poltreg S.A. Receives CGMP Certification to Produce Cell Therapies At Its State-Of-The-Art Manufacturing Site in Poland	CI

Poltreg SA is a Poland-based company engaged primarily in biotechnology and medical research. The Company conducts research in the field of autoimmunological diseases. The Company works on a method of healing, that uses t-regulated cells (TREGs). The Firm possesses its own, patented technology to obtain T-regulated lymphocytes, that are used in the therapy. The Company works on therapy for diseases such as type one diabetes, type two diabetes, and multiple sclerosis. In its research, the Company cooperates with multiple specialists from various fields of science. The Company is developing its own research center, which is intended as a basic location for conducting future research activities.

Number of employees: 23

Managers	Title	Age	Since
Piotr Trzonkowski CEO	Chief Executive Officer	-	14-12-31
Paulina Kocenko-Merks DFI	Director of Finance/CFO	-	23-02-28
Marta Druch CTO	Chief Tech/Sci/R&D Officer	-	-
Kamilla Agnieszka Bok COO	Chief Operating Officer	-	18-06-30
Mariusz Jablonski PRN	Corporate Officer/Principal	-	19-12-08

Members of the board	Title	Age	Since
Oktawian Zbigniew Jaworek BRD	Director/Board Member	48	21-05-20
Artur Janusz Osuchowski BRD	Director/Board Member	49	21-07-14
Marcin Jerzy Mierzwiñski CHM	Chairman	-	21-05-23
Wojciech Golak BRD	Director/Board Member	41	-
Jacek Gdanski BRD	Director/Board Member	-	21-07-14

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	4,663,448	3,015,848 ( 64.67 %)	0	64.67 %

Name	Equities	%	Valuation
Paan Capital Sp zoo Spk 21.31 %	993,602	21.31 %	12 M zł
IPOPEMA TFI SA (Venture Capital) 19.83 %	924,789	19.83 %	11 M zł
Allianz Polska PTE SA 7.634 %	356,000	7.634 %	4 M zł
Trzonkowska Marek 5.243 %	244,499	5.243 %	3 M zł
Piotr Trzonkowski 5.243 %	244,499	5.243 %	3 M zł
Allianz Polska TFI SA 4.006 %	186,800	4.006 %	2 M zł
Malgorzata Mysliwiec 3.538 %	165,000	3.538 %	2 M zł
Artur Janusz Osuchowski 0.2680 %	12,500	0.2680 %	154 153 zł
Aviva Investors Poland Towarzystwo Funduszy Inwestycyjnych SA 0.000000 %	0	0.000000 %	- zł

PolTREG SA

ul. Botaniczna 20

80-298, Gdansk

+48 512 53 24 01

http://www.poltreg.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

49 PLN

Average target price

68.2 PLN

Spread / Average Target

+39.18%

Consensus

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
POLTREG S.A.	-0.80%	57.87M
MODERNA, INC.	+29.61%	49.18B
IQVIA HOLDINGS INC.	+0.80%	42.11B
LONZA GROUP AG	+50.47%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+13.66%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.76%	18.71B
BIO-TECHNE CORPORATION	+8.46%	13.26B
MEDPACE HOLDINGS, INC.	+32.20%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.24%	11.99B

Other Biotechnology & Medical Research